Immuneering Corporation
NGM: IMRXLive Quote
📈 ZcoreAI Score
Our AI model analyzes Immuneering Corporation's price action across multiple timeframes using regression channels and statistical scoring.
Get IMRX Z-Score →About Immuneering Corporation
Healthcare
Biotechnology
Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inhibitor discovery programs. The company has clinical supply agreements with Regeneron Pharmaceuticals to evaluate atebimetinib in combination with Libtayo in patients with unresectable or metastatic RAS-mutant non-small cell lung cancer; and with Eli Lilly and Company to evaluate atebimetinib in combination with olomorasib in patients with advanced or metastatic KRAS G12C-mutant non-small cell lung cancer. Immuneering Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
📊 Fundamental Analysis
Immuneering Corporation demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -43.1%, which indicates that capital utilization is currently under pressure.
At a current price of $5.52, IMRX currently sits at the 49th percentile of its 52-week range (Range: $1.10 - $10.08).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Debt/Equity
Elevated
🔴
Return on Equity
Weak
✅
Beta (Risk)
Low Volatility
Key Financials
Market Cap
$356.88M
Trailing P/E
--
Forward P/E
-4.08
Beta (5Y)
0.43
52W High
$10.08
52W Low
$1.10
Avg Volume
1.06M
Day High
Day Low